I think gastrointestinal stromal tumors are just really leading the way in terms of the use of ctDNA in assessing disease response and disease status. As I mentioned, the randomized trial of ripretinib versus sunitinib, a second-line therapy in patients with kit exon 11 and kit exon 17 and 18 CT DNA positive disease will be absolutely informative in terms of the role of ctDNA in metastatic GIST and will hopefully lead to further evaluation in other sarcoma subtypes...
I think gastrointestinal stromal tumors are just really leading the way in terms of the use of ctDNA in assessing disease response and disease status. As I mentioned, the randomized trial of ripretinib versus sunitinib, a second-line therapy in patients with kit exon 11 and kit exon 17 and 18 CT DNA positive disease will be absolutely informative in terms of the role of ctDNA in metastatic GIST and will hopefully lead to further evaluation in other sarcoma subtypes.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
